Beam Therapeutics(US:BEAM) ZACKS·2025-11-04 14:37分组1 - Beam Therapeutics Inc. reported a quarterly loss of $1.1 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.98, representing an earnings surprise of -12.24% [1] - The company posted revenues of $9.7 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 25.31%, and down from $14.27 million in the same quarter last year [2] - Over the last four quarters, Beam Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] 分组2 - The stock has underperformed the market, losing about 2.2% since the beginning of the year, while the S&P 500 gained 16.5% [3] - The current consensus EPS estimate for the coming quarter is -$1.02 on revenues of $14.01 million, and for the current fiscal year, it is -$4.23 on revenues of $42.91 million [7] - The Medical - Biomedical and Genetics industry, to which Beam Therapeutics belongs, is currently in the top 39% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]